TherapyIlium Osteitis as the Main Manifestation of the SAPHO Syndrome: Response to Infliximab Therapy and Review of the Literature
Section snippets
Methods
We report 2 patients with the SAPHO syndrome treated with infliximab and retrospectively reviewed patients seen in our department between 2000 and 2007. Additionally, a computer-assisted (MEDLINE, National Library of Medicine, Bethesda, MD) literature search was accomplished to locate all reports of SAPHO syndrome treated with TNF-α blockers published in English since 1999, when TNF-α blockers became commercially available. Cases reported in abstracts from European League Against Rheumatism and
Case Report 1
A 45-year-old woman with no other relevant medical history complained of pain in the right buttock, accompanied by occasional fever and asthenia at 21 years of age. Radiographs showed right sacroiliitis and bone scintigraphy showed mild uptake in the right sacroiliac joint. The patient was HLA-B27 negative. Mild, pustular skin lesions on the palms of the hands appeared several months after the first visit (November 1989). An initial diagnosis of psoriatic arthritis was made based on the
Results
Eighteen patients were identified in the literature search (13 women and 5 men) including 16 reported cases (5, 6, 7, 8, 9, 10, 11, 12) and 2 unpublished cases from our unit. Seventeen patients had SAPHO syndrome and 1 patient had chronic recurrent multifocal osteomyelitis. The clinical characteristics are shown in Table 1.
The mean age at introduction of anti-TNF-α therapy was 42.3 ± 14 years (range, 16-67 years). All patients had osteoarticular features, including chest wall involvement in 16
Discussion
We describe 2 cases of the SAPHO syndrome the main manifestation of which was extensive osteitis of the ilium that initially presented as sacroiliitis without involvement of the anterior chest wall or skin lesions. This unusual presentation of the SAPHO syndrome led us to make a differential diagnosis with various bone and joint disorders including spondyloarthropathy, osteomyelitis, primary bone malignancy, hematological conditions such as lymphoma, and even Paget’s disease of the bone.
References (22)
- et al.
SAPHO syndrome: a long-term follow-up study of 120 cases
Semin Arthritis Rheum
(1999) - et al.
Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab
J Am Acad Dermatol
(2005) - et al.
The SAPHO syndrome
Baillieres Clin Rheumatol
(1994) - et al.
Le syndrome pustulose hyperostose osteite (SAPHO). Resultats d’une enquête nationale: 85 observations
Rev Rhum Mal Osteoartic
(1987) - et al.
Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (Sapho): a new syndrome among the spondyloarthropathies?
Clin Exp Rheumatol
(1988) - et al.
Pharmacological management of SAPHO syndrome
Exp Opin Investig Drugs
(2006) - et al.
Sustained response to tumor necrosis factor α-blocking agents in two patients with SAPHO syndrome
Arthritis Rheum
(2002) - et al.
Successful treatment of SAPHO syndrome with infliximab: report of two cases
Ann Rheum Dis
(2002) - et al.
Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-α blockage
Pediatrics
(2005) - et al.
In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations
Rheumatology
(2006)
Infliximab in the treatment of SAPHO syndrome: clinical experience and MRI response
Ann Rheum Dis
Cited by (70)
A case of spondylitis caused by SAPHO syndrome treated with oblique lateral interbody fusion
2022, Interdisciplinary Neurosurgery: Advanced Techniques and Case ManagementTumor Necrosis Factor Inhibitors
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionBiologics in SAPHO syndrome: A systematic review
2019, Seminars in Arthritis and RheumatismSAPHO and Recurrent Multifocal Osteomyelitis
2017, Radiologic Clinics of North AmericaEvidence-based recommendations for the management of acne fulminans and its variants
2017, Journal of the American Academy of DermatologyCitation Excerpt :The biologic agents etanercept and infliximab have been successfully used to treat isotretinoin-resistant acne conglobata in a few case reports.29-31 In addition, the acne lesions of SAPHO might respond to tumor necrosis factor–α inhibitors, primarily infliximab.32-35 Tumor necrosis factor–α inhibitors, anakinra (an IL-1 receptor antagonist), and canakinumab (an anti–IL-1β monoclonal antibody) have reported efficacy in treating acne in PAPA and PAPASH syndromes.36-39
SAPHO: Treatment options including bisphosphonates
2016, Seminars in Arthritis and RheumatismCitation Excerpt :The use of antibiotics has not been effective in general [3,7,32,33]. Favorable results with anti-tumor necrosis factor drugs (anti-TNF) have been described in case reports and small series [38–45]. However, the most promising results have been observed in patients under treatment with bisphosphonates [2,46–52].